Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Adv Gerontol ; 33(2): 319-324, 2020.
Article in Russian | MEDLINE | ID: mdl-32593247

ABSTRACT

To identify predictors of neurological complications in the hospital period after coronary artery bypass grafting (CABG), 92 patients with coronary heart disease aged 70 years and over were analyzed. Intraoperative monitoring of cerebral oxygenation (rSO2, %) was carried out. At the stage of induction anesthesia, the average level of rSO2 for left and right hemispheres was 64-65% without significant changes during the operation. A decrease in rSO2 during cardiopulmonary bypass (CPB) was associated with increased risk of neurological complications. The risk of neurological complications increase 7-fold and 9-fold with a decrease in rSO2 by 20% or more during CPB relative to baseline for left and right hemispheres, respectively. A history of two or more myocardial infarctions increases 3-fold the risk of neurological complications after CABG.


Subject(s)
Coronary Artery Bypass/adverse effects , Coronary Disease/surgery , Nervous System Diseases/diagnosis , Nervous System Diseases/etiology , Postoperative Complications/diagnosis , Aged , Aged, 80 and over , Cardiopulmonary Bypass/adverse effects , Coronary Disease/complications , Humans , Myocardial Infarction/complications , Myocardial Infarction/surgery , Postoperative Complications/etiology
2.
Angiol Sosud Khir ; 25(4): 167-172, 2019.
Article in Russian | MEDLINE | ID: mdl-31855214

ABSTRACT

Pulmonary haemorrhage is one of the most severe complications of pulmonary endarterectomy. To the most effective methods of combating this potentially fatal complication belongs extracorporeal membrane oxygenation (ECMO). In this article we describe a clinical case report regarding intraoperative use of central veno-arterial ECMO for pulmonary haemorrhage following thromboendarterectomy from the pulmonary arteries. According to the data of some authors, long-term ECMO support (for more than 4 days) may lead to such severe consequences as rethrombosis of pulmonary arteries and impairment of cerebral circulation. In our case we managed to avoid such complications, taking into consideration that the duration of ECMO amounted to 21 days. Resulting from the carried out comprehensive therapeutic measures by the time of discharge from hospital, a significant decrease in pulmonary artery pressure was achieved, with events of residual pulmonary hypertension.


Subject(s)
Endarterectomy/adverse effects , Extracorporeal Membrane Oxygenation , Hemorrhage/surgery , Lung Diseases/surgery , Pulmonary Embolism/surgery , Hemorrhage/etiology , Humans , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/therapy , Lung Diseases/etiology
3.
Anesteziol Reanimatol ; 60(1): 33-8, 2015.
Article in Russian | MEDLINE | ID: mdl-26027222

ABSTRACT

INTRODUCTION: Remote ischemic preconditioning has gained clinicians' attention as a technique to protect the heart in patients undergoing cardiac surgery under cardiopulmonary bypass. While experimental data report neuroprotective properties of remote ischemic preconditioning, we failed to find any clinical studies investigating its effects on neurologic outcome in cardiac surgery. PURPOSE OF THE STUDY: This prospective randomized placebo-controlled study was undertaken with the aim of elucidating the role of remote ischemic preconditioning for neuroprotection in cardiac surgery. PATIENTS AND METHODS: 88 patients with coronary heart disease scheduled for on-pump coronary bypass grafting surgery were randomized to receive either remote ischemic preconditioning or control. We studied S100B peptide and neuron-specific enolase to assess neurological damage. Psychophysiological tests were employed to investigate cognitive function after surgery. RESULTS: The perioperative dynamics of S100B and neuron-specific enolase followed similar patterns in both groups throughout the observation period. At the end of surgery, level of S100B was significantly higher in the preconditioning group as compared to controls--0.58 (0.33-0.65) vs. 0.34 (0.23-0.42) mcg/l, p

Subject(s)
Brain Ischemia/prevention & control , Cardiopulmonary Bypass , Ischemic Preconditioning/methods , Myocardial Revascularization , Phosphopyruvate Hydratase/blood , S100 Calcium Binding Protein beta Subunit/blood , Biomarkers/blood , Brain Ischemia/blood , Brain Ischemia/etiology , Brain Ischemia/psychology , Cardiopulmonary Bypass/adverse effects , Cognition/physiology , Female , Humans , Lower Extremity/blood supply , Male , Middle Aged , Myocardial Ischemia/surgery , Myocardial Revascularization/adverse effects , Neuropsychological Tests , Prospective Studies
4.
Int J Cardiol ; 176(1): 20-31, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25022819

ABSTRACT

BACKGROUND: A number of 'proof-of-concept' trials suggest that remote ischaemic preconditioning (RIPC) reduces surrogate markers of end-organ injury in patients undergoing major cardiovascular surgery. To date, few studies have involved hard clinical outcomes as primary end-points. METHODS: Randomised clinical trials of RIPC in major adult cardiovascular surgery were identified by a systematic review of electronic abstract databases, conference proceedings and article reference lists. Clinical end-points were extracted from trial reports. In addition, trial principal investigators provided unpublished clinical outcome data. RESULTS: In total, 23 trials of RIPC in 2200 patients undergoing major adult cardiovascular surgery were identified. RIPC did not have a significant effect on clinical end-points (death, peri-operative myocardial infarction (MI), renal failure, stroke, mesenteric ischaemia, hospital or critical care length of stay). CONCLUSION: Pooled data from pilot trials cannot confirm that RIPC has any significant effect on clinically relevant end-points. Heterogeneity in study inclusion and exclusion criteria and in the type of preconditioning stimulus limits the potential for extrapolation at present. An effort must be made to clarify the optimal preconditioning stimulus. Following this, large-scale trials in a range of patient populations are required to ascertain the role of this simple, cost-effective intervention in routine practice.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Cardiovascular Diseases/surgery , Electronic Health Records , Ischemic Preconditioning, Myocardial/methods , Postoperative Complications , Adult , Cardiovascular Diseases/diagnosis , Humans , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Randomized Controlled Trials as Topic/methods
5.
Anesteziol Reanimatol ; (2): 14-8, 2012.
Article in Russian | MEDLINE | ID: mdl-22834281

ABSTRACT

It was conducted a study of glutamine cardioptotective effects during perioperative use in patients with ischemic heart disease, operated under CB. Exclusion criteria were: left ventricular ejection fraction less than 50%, diabetes melitus, myocardial infarction less than 3 months ago, Patients of the study group (n=25) had glutamine (20% solution N(2)-L-alanine-L-glutamine ("Dipeptiven" Fresenius Kabi, Germany); 0.4 g/kg/day. Patients of control group (n=25) received placebo (0.9% NaCl solution). The main indicators were the dynamics of troponin I, as well as central hemodynamics parameters. On the 1-st day after operation the concentration of troponin I was significantly lower in the glutamine-group compared placebo-group (1.280 (0.840-2.230) 2.410 (1.060-6.600) ng/ml; p=0.035). 4 hours after CB in a glutamine-group also had significantly large indicators of cardiac index (2.58 (2.34-2.91) l/min/m2 vs 2.03 (1.76-2.32)) l/min/m2; p=0,002) and stroke index (32.8 (27.8-36.0.) ml/m2 vs 26.1 (22.6-31.8) ml/m2; p=0.023). Systemic vascular resistance index was significantly lower in glutamine-group (1942 (1828-2209) dyn x s/cm(-5)/m2 vs 2456 (2400-3265) dyn x s/cm(-5)/m2; p=0.001). Conclusion. Perioperative use of N(2)-L-alanine-L-glutamine during the first 24 hours ofperioperative period gives cardioprotective effect in patients with ischemic heart disease operated under CB.


Subject(s)
Cardiac Surgical Procedures/methods , Cardiotonic Agents/therapeutic use , Extracorporeal Circulation , Glutamine/therapeutic use , Myocardial Ischemia/surgery , Myocardial Reperfusion Injury/prevention & control , Cardiac Surgical Procedures/adverse effects , Cardiotonic Agents/administration & dosage , Double-Blind Method , Female , Glutamine/administration & dosage , Humans , Intraoperative Care , Male , Middle Aged , Myocardial Reperfusion Injury/blood , Myocardial Reperfusion Injury/etiology , Treatment Outcome , Troponin I/blood
6.
Anesteziol Reanimatol ; (3): 10-3, 2008.
Article in Russian | MEDLINE | ID: mdl-18652167

ABSTRACT

The aim of the study was to assess the use of gelofusine and voluven for acute normovolemic hemodilution at cardiac surgery under extracorporeal circulation (EC). Sixty-seven patients with coronary heart disease were examined. Heart rate, total peripheral vascular resistance, pulmonary pressure, pulmonary artery wedge pressure, oxygen delivery and consumption, central venous pressure, arteriovenous oxygen difference, oncotic pressure, and postoperative clinical course were studied. No significant group differences were found in indices, other than arteriovenous oxygen difference, after acute normovolemic hemodilution and in central venous pressure following 6 hours of EC termination. The administration of gelofusine caused a more steady-state oxygen-transport function of the circulatory system. The use of the agent for acute normovolemic hemodilution at cardiac surgery under EC is more economically justified than that of volumen.


Subject(s)
Heart Arrest, Induced/methods , Hemodilution/methods , Hydroxyethyl Starch Derivatives , Myocardial Ischemia/surgery , Plasma Substitutes , Polygeline , Coronary Artery Bypass/methods , Extracorporeal Circulation , Hemodynamics/drug effects , Humans , Hydroxyethyl Starch Derivatives/administration & dosage , Hydroxyethyl Starch Derivatives/therapeutic use , Plasma Substitutes/administration & dosage , Plasma Substitutes/therapeutic use , Polygeline/administration & dosage , Polygeline/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...